Biocept (NASDAQ:BIOC) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Biocept (NASDAQ:BIOC – Get Rating) in a research note published on Saturday morning. The firm issued a hold rating on the medical research company’s stock.

Several other research analysts have also recently commented on the stock. Brookline Capital Management cut shares of Biocept from a buy rating to a hold rating in a report on Friday, January 6th. Maxim Group lowered shares of Biocept from a buy rating to a hold rating in a report on Friday, April 14th.

Biocept Price Performance

NASDAQ:BIOC opened at $0.26 on Friday. The firm has a market cap of $4.54 million, a PE ratio of -0.13 and a beta of 0.92. Biocept has a 12 month low of $0.24 and a 12 month high of $1.75. The company has a quick ratio of 2.83, a current ratio of 2.97 and a debt-to-equity ratio of 0.14. The company’s 50-day moving average price is $0.34 and its two-hundred day moving average price is $0.53.

Institutional Investors Weigh In On Biocept

A hedge fund recently raised its stake in Biocept stock. Renaissance Technologies LLC grew its position in shares of Biocept, Inc. (NASDAQ:BIOC – Get Rating) by 27.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 116,400 shares of the medical research company’s stock after acquiring an additional 24,800 shares during the quarter. Renaissance Technologies LLC owned about 0.69% of Biocept worth $270,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Biocept Company Profile

(Get Rating)

Biocept, Inc is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.